The Researcher Sample Clauses

The Researcher. The Research Services will be performed by Xxxx Xxxxx, D.V.S., a doctoral student working under the supervision and responsibility of Xxxxxxxxx Xxxxxxxxx Xxxxxxxxx, or such other qualified person as may be determined and appointed from time to time by Yissum (the “Res earcher”).
Sample 1
AutoNDA by SimpleDocs
The Researcher. The Researcher is a “Xxxxx Xxxxxxxxxx-Xxxxx Fellow”. They are appointed as a member of staff at NTNU (see Contract of Employment). The Terms and Conditions of the employment are the same as those of other members of staff at NTNU appointed at a similar level. The duration of the period of the MSCA Fellowship will be: Start date: (Fill in) End date: (Fill in) The Researcher must conduct the MSCA research project according to the XX Xxxxx Agreement for: MSCA Fellowship Project Acronym: (Fill in) MSCA Fellowship Project Title: (Fill in) XX Xxxxx Agreement No: (Fill in) The location of the MSCA Fellowship will be NTNU, Campus XXX, Department XXX. The Researcher will be supervised during their stay at NTNU by (Fill in - Title, Name), hereinafter referred to as the "Supervisor(s)".
Sample 1Sample 2
The Researcher. 3.1 The Research will be performed by, or under the control and supervision of, Pxxxxxxxx Xxxxxx Xxxxxxxx (the “Researcher”). In the event that the Researcher, for any reason whatsoever, shall be unable to conduct the Research, or shall cease to be available for the performance of the undertakings set forth in this Agreement, Yissum shall use its best efforts to appoint, within 30 (thirty) days, a successor researcher whose identity shall be approved in advance by the Company (the “Successor Researcher”). Upon the Successor Researcher’s appointment, the Successor Researcher shall be deemed to be a Researcher for all purposes herein. Should the Parties not be able to agree on the identity of a Successor Researcher, notwithstanding their best efforts to do so, the Company shall have the right to terminate the Research and will bear no liability for such termination, provided that (i) no monies paid to Yissum for the Research pursuant to Section 5.1, below, will be refunded by Yissum to the Company, and (ii) the Company shall be responsible for the payment of any accrued fees and expenses due to Yissum based on work duly performed up to the date of termination and those irrevocable commitments entered into by Yissum prior to having received the Company’s written notice of termination.
Sample 1
The Researcher. The Services will be performed by or under the sole control and supervision of Dx. Xxxxx Xxxxxxx, or such other qualified person as may be determined and appointed by Yissum, provided that the Company has authorized in advance and in writing the appointment of such qualified person (the “Researcher”).
Sample 1
The Researcher. The Services will be performed by or under the control and supervision of Prof. Avi Domb or such other qualified person as may be determined and appointed from time to time by Yissum (the “Researcher”).
Sample 1
The Researcher. The researcher is more often than not driven by a desire to see their work being used in some way or other. Whether that is seeing something on the shelves in the local shops or seeing a product being used beneficially by someone, the result is the same and brings a sense of satisfaction. The researcher also wants to be able to do more research. This may sound obvious, but researchers don’t like to be prevented from doing their work by IPR limitations, and they see themselves as free thinkers who come up with great ideas. Of course, money is still a motivation, and a researcher will often believe that their ideas have a high commercial value. This isn’t always true, and it may be that a great idea doesn’t offer a commercial organisation the opportunity to make the all-important profit, but this is not always obvious to the researcher owning the IP. In order to achieve these objectives, the researcher has a number of routes to market that they can take, each with advantages and disadvantages which must be carefully weighed up. On the assumption that the researcher has created a piece of identifiable intellectual property (IP) in the form perhaps of software, algorithm, design or simply unique knowledge, the first decision is whether to make the IP publically accessible or to retain ownership and aim to gain financial benefit from its exploitation. Software can be made available open source, or knowledge can be published in a publically accessible forum. This has the advantage that there is no obligation on the researcher to maintain or develop the research any further – anyone making use of their ideas might be expected to acknowledge its provenance, but would be free to make their own implementation and would take on the costs of development and support. The disadvantage to the researcher would be a loss of control over their ideas, and loss of any financial benefit that might accrue. A half- way house that is available is to release designs or software as “dual license”. This means that, for certain specified applications such as non-profit research, the IP can be used with an acknowledgement and without compromising original ownership. Any commercial exploitation of the IP would be licensed from the researcher. For their part, the researcher must ensure that the IP does not incorporate any “viral” open source elements (which corrupt the IP they are built into) or any commercial components, which may be used under an academic license during the research p...
Sample 1

Related to The Researcher

  • Research Support opioid abatement research that may include, but is not limited to, the following:

  • Research Matters By entering into this Agreement, the Placement Agent does not provide any promise, either explicitly or implicitly, of favorable or continued research coverage of the Company and the Company hereby acknowledges and agrees that the Placement Agent’s selection as a placement agent for the Offering was in no way conditioned, explicitly or implicitly, on the Placement Agent providing favorable or any research coverage of the Company. In accordance with FINRA Rule 2711(e), the parties acknowledge and agree that the Placement Agent has not directly or indirectly offered favorable research, a specific rating or a specific price target, or threatened to change research, a rating or a price target, to the Company or inducement for the receipt of business or compensation.

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Research Program 2.1 University will use reasonable efforts to conduct the Research Program described in Attachment A which is hereby incorporated in full by reference (“Research Program”), and will furnish the facilities necessary to carry out said Research Program. The Research Program will be under the direction of _____________________ (“Principal Investigator”), or his or her successor as mutually agreed to by the Parties and will be con­ducted by the Principal Investigator at the University.

  • Inventions Retained and Licensed I have attached hereto, as Exhibit A, a list describing all inventions, original works of authorship, developments, improvements, and trade secrets which were made by me prior to my employment with the Company (collectively referred to as “Prior Inventions”), which belong to me, which relate to the Company’s proposed business, products or research and development, and which are not assigned to the Company hereunder; or, if no such list is attached, I represent that there are no such Prior Inventions. If in the course of my employment with the Company, I incorporate into a Company product, process or machine a Prior Invention owned by me or in which I have an interest, the Company is hereby granted and shall have a nonexclusive, royalty-free, irrevocable, perpetual, worldwide license to make, have made, modify, use and sell such Prior Invention as part of or in connection with such product, process or machine.

  • By Client Client agrees to indemnify, defend and hold Agency, its officers, directors, employees, agents, attorneys, subsidiaries, affiliated companies, parent companies, representatives, and successors and assigns, harmless from and against all Losses to the extent such Losses arise out of or are primarily related to (i) the negligent or wrongful acts, errors, or omissions of Client or its employees, agents affiliates, assigns or any creditor or prior account holder, or the employees or agents of any of them, in connection with this Agreement, including but not limited to errors or omissions in connection with information furnished by Client to Agency concerning a Referred Account, or (ii) any collection effort by Client or any other collection agency as to a Referred Account.

  • Research Funding Genocea shall pay to Isconova in total [* * *] payable as follows: (i) $[* * *] in equal monthly installments for each remaining month in 2009 following the Effective Date and (ii) $[* * *] in equal monthly installments during the period from January 1, 2010 until March 31, 2012. The Research Funding shall be used solely for the performance of activities under the Research and Phase 1 Supply Plan and the Development and Scale-Up Plan and, for the avoidance of doubt, solely to fund Development and research activities for human (and not veterinary) applications in accordance with such Research and Phase 1 Supply Plan and Development and Scale-Up Plan. Notwithstanding anything to the contrary above, the Parties agree that this restriction shall only apply to the allocation and use of the Research Funding as such, and shall not be construed as limiting or affecting the ownership of any Isconova Technology and Joint Technology created, conceived, reduced to practice or Invented hereunder. Isconova’s ownership and/or rights to the Isconova Technology and Joint Technology shall exclusively be governed by the provisions in Section 3.3. and Isconova’s use of the Isconova Technology and Joint Technology shall be subject only to the licenses granted to Genocea in Sections 3.1.1 through 3.1.3. Isconova shall during the Research Term allocate not less than two (2) dedicated FTEs for Isconova’s research work for Genocea hereunder and each such dedicated FTE shall be paid through Research Funding. During the Research Term, Isconova shall, within fifteen (15) days after the end of each month, deliver to Genocea a report setting forth the number of Isconova FTEs that worked on activities under the Development and Scale-Up Plan and the Research and Phase 1 Supply Plan, as well as other costs and expenses of Isconova evidencing recourses spent on Isconova’s research work hereunder. Researching Funding THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. payments shall be made within fifteen (15) days after the end of each calendar month.

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.

  • Technology Transfer Subject to the terms of the Development Supply Agreement, as soon as reasonably practicable, but in no event later than the fifth (5th) anniversary of the Effective Date, Alnylam shall initiate a technology transfer to MedCo, or to its Third Party manufacturer(s) of Licensed Product, selected by MedCo and reasonably acceptable to Alnylam, of Alnylam Know-How that is reasonably necessary or useful for the Manufacture of the Licensed Product, and shall make available its personnel on a reasonable basis to consult with MedCo or such Third Party manufacturer(s) with respect thereto, all at MedCo’s expense, including the Costs reasonably incurred by Alnylam in connection with such technology transfer activities. MedCo shall reimburse Alnylam such Costs incurred with respect to such Manufacturing technology transfer within [***] days after receipt of an invoice therefor. Alnylam and its Affiliates shall keep complete and accurate records in sufficient detail to enable the payments payable hereunder to be determined. Alnylam shall not be required to perform technology transfer to more than one Third Party manufacturer for each stage of the Licensed Product supply chain (i.e., Bulk Drug Substance, Bulk Drug Product and Finished Product). Promptly after MedCo’s written request, Alnylam shall use Commercially Reasonable Efforts to assign to MedCo any manufacturing agreement between Alnylam and a Third Party that is solely related to the manufacture of Licensed Products. Such assignment shall be subject to the terms and conditions of such agreement, including any required consents of such Third Party and MedCo’s written agreement to assume all the obligations of Alnylam under such agreement to be undertaken after such assignment, but Alnylam shall remain solely responsible for its obligations under such agreement arising prior to such assignment. Except as provided in the immediately preceding sentence, MedCo shall be solely responsible for contracting with such Third Party manufacturer (and any other Third Party manufacture to whom Alnylam has initiated technology transfer as set forth in this Section 5.3) for the supply of such Licensed Product and Alnylam shall have no obligations under such agreement between MedCo and such Third Party manufacturer. Alnylam shall use Commercially Reasonable Efforts to obtain any such consent in a form reasonably acceptable to MedCo.

Time is Money Join Law Insider Premium to draft better contracts faster.